[go: up one dir, main page]

AR058576A1 - Compuestos con efectos medicinales debido a la interaccion con el receptor glucocorticoide - Google Patents

Compuestos con efectos medicinales debido a la interaccion con el receptor glucocorticoide

Info

Publication number
AR058576A1
AR058576A1 ARP060105643A ARP060105643A AR058576A1 AR 058576 A1 AR058576 A1 AR 058576A1 AR P060105643 A ARP060105643 A AR P060105643A AR P060105643 A ARP060105643 A AR P060105643A AR 058576 A1 AR058576 A1 AR 058576A1
Authority
AR
Argentina
Prior art keywords
optionally halogenated
hydrogen
alkyl
halogen
optionally
Prior art date
Application number
ARP060105643A
Other languages
English (en)
Inventor
N M Hamilton
S J A Grove
M J Kiczun
J R Morphy
B Sherborne
D T Littlewood
A R Brown
C L Kingsbury
M Ohlmeyer
K K Ho
S G Kultgen
Original Assignee
Organon Nv
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv, Pharmacopeia Drug Discovery filed Critical Organon Nv
Publication of AR058576A1 publication Critical patent/AR058576A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion proporciona compuestos con la estructura de acuerdo con la formula (1) donde: X es un átomo de nitrogeno o carbono, Ar es anillo heteroaromático o fenil; R1 es hidrogeno, halogeno, CN o (1C-4C)alquil; R2 es hidrogeno, halogeno o (1C- 3C)alcoxi opcionalmente fluorado; R3 y R5 son independientemente hidrogeno, (1C-4C)alquil opcionalmente halogenado, (1C-4C)alcoxi opcionalmente halogenado, aril(1C-4C)alcoxi opcionalmente halogenado, (1C-4C)alquenil opcionalmente halogenado o hidroximetil; R4 es hidrogeno, halogeno, (1C-4C)alcoxi opcionalmente halogenado o aril(1C-4C)alcoxi opcionalmente halogenado; R6 es hidrogeno, benzil, opcionalmente sustituido con uno o más halogenos o (1C-4C)alquil, o R6 es (1C-4C)alquil opcionalmente halogenado; cada R7 independientemente es hidrogeno, halogeno, (1C-4C)alquil opcionalmente halogenado o (1C-4C)alcoxi opcionalmente halogenado y sales de adicion de ácido farmacéuticamente adecuadas de ellos para utilizar como moduladores del receptor glucocorticoide, en particular para el tratamiento de los desordenes del sustema nervioso central.
ARP060105643A 2005-12-21 2006-12-20 Compuestos con efectos medicinales debido a la interaccion con el receptor glucocorticoide AR058576A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75252605P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
AR058576A1 true AR058576A1 (es) 2008-02-13

Family

ID=37902853

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105643A AR058576A1 (es) 2005-12-21 2006-12-20 Compuestos con efectos medicinales debido a la interaccion con el receptor glucocorticoide

Country Status (19)

Country Link
US (1) US7960365B2 (es)
EP (1) EP1965785A1 (es)
JP (1) JP5319299B2 (es)
KR (1) KR20080086482A (es)
CN (1) CN101534811A (es)
AR (1) AR058576A1 (es)
AU (1) AU2006328550B2 (es)
BR (1) BRPI0620184A2 (es)
CA (1) CA2631816C (es)
EC (1) ECSP088602A (es)
IL (1) IL191815A0 (es)
MX (1) MX2008007681A (es)
NO (1) NO20082436L (es)
NZ (1) NZ569011A (es)
PE (1) PE20071170A1 (es)
RU (1) RU2430086C2 (es)
TW (1) TW200800150A (es)
WO (1) WO2007071638A1 (es)
ZA (1) ZA200804643B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103479604B (zh) * 2007-07-30 2016-08-10 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
US8299048B2 (en) * 2008-03-06 2012-10-30 Merck Sharp & Dohme Corp. Hexahydrocyclopentyl[f]indazole sulfonamides and derivatives thereof as selective glucocorticoid receptor modulators
EP2524057B1 (en) * 2010-01-15 2016-03-30 Rigel Pharmaceuticals, Inc. Screening assay employing dex and gdf8
US20130190356A1 (en) * 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
WO2018005801A2 (en) * 2016-07-01 2018-01-04 Venenum Biodesign Llc Novel non-systemic tgr5 agonists
US10981918B2 (en) * 2018-07-20 2021-04-20 Grünenthal GmbH Further substituted triazolo quinoxaline derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
WO1996036595A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
EA011095B1 (ru) 2002-08-29 2008-12-30 Бёрингер Ингельхайм Фармасьютиклз, Инк. Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
US20060135773A1 (en) * 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
SE0402635D0 (sv) * 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
AU2006328550B2 (en) 2012-04-12
JP5319299B2 (ja) 2013-10-16
EP1965785A1 (en) 2008-09-10
US20070149577A1 (en) 2007-06-28
MX2008007681A (es) 2008-10-23
ZA200804643B (en) 2009-03-25
IL191815A0 (en) 2008-12-29
PE20071170A1 (es) 2007-11-30
WO2007071638A1 (en) 2007-06-28
NO20082436L (no) 2008-09-08
NZ569011A (en) 2011-04-29
TW200800150A (en) 2008-01-01
KR20080086482A (ko) 2008-09-25
CA2631816C (en) 2014-05-06
CA2631816A1 (en) 2007-06-28
RU2430086C2 (ru) 2011-09-27
AU2006328550A1 (en) 2007-06-28
US7960365B2 (en) 2011-06-14
ECSP088602A (es) 2008-08-29
RU2008129667A (ru) 2010-01-27
BRPI0620184A2 (pt) 2011-11-01
CN101534811A (zh) 2009-09-16
JP2009526749A (ja) 2009-07-23

Similar Documents

Publication Publication Date Title
CR6616A (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
PE20030039A1 (es) Derivados de indol con afinidad por el receptor 5-ht6
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PE20050767A1 (es) Amino-benzazoles como inhibidores del receptor p2y1
PE20191495A1 (es) Piridonamidas como moduladores de canales de sodio
ATE534625T1 (de) Substituierte n-phenyl-bipyrrolidinharnstoffe und deren therapeutische verwendung
CO6321153A2 (es) Derivados de cromeno y cromano y sus usos
SV2002000022A (es) Inhibidores de recanalizacion de la monoamida para el tratamiento de los desordenes del sistema nervioso central ref. pc10434
UY24016A1 (es) Derivados triciclicos del pirazol
BRPI0511907A (pt) novos derivados de fenilpiperidinas/piperizinas dissubstituìdos como moduladores da neurotransmissão de dopamina
PE41796A1 (es) Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c.
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
ECSP088602A (es) Compuestos con efectos medicinales debido a la interacción con el receptor de glucocorticoides
PE20091167A1 (es) Derivados heterociclicos con actividad sobre los receptores de ampa
AR055171A1 (es) Derivados de carboxamida como antagonistas del receptor muscarinico
UY27998A1 (es) Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia
AR035818A1 (es) Fenil-heterociclil-eteres con actividad como inhibidores selectivos de recaptacion de serotonina, composiciones farmaceuticas y su uso en la fabricacion de medicamentos
DE60009544D1 (de) Il-8 rezeptor antagonisten
ATE449082T1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor
PE20091187A1 (es) Compuestos derivados de quinolina como moduladores del receptor de serotonina 5-ht6
ECSP088147A (es) Moduladores del receptor de la cianopirrol-sulfonamida progesterona y los usos de los mismos
PE20020436A1 (es) Derivados de tetrahidropirano como antagonistas del receptor de neuroquinina 1 (nk-1)
ECSP045292A (es) Proceso para la preparación de piperazines quirales 1,4-disustituidas
PA8802201A1 (es) Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6

Legal Events

Date Code Title Description
FB Suspension of granting procedure